These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 23908475

  • 1. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.
    Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Makutu DK, Nfanyana K, Rantleru T, Tierney A, Nkakana K, Schwartz AB, Gross R, Macgregor RR, Bellamy SL, Frank I, Weissman D, Bisson GP.
    J Infect Dis; 2013 Dec 01; 208(11):1784-93. PubMed ID: 23908475
    [Abstract] [Full Text] [Related]

  • 2. Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.
    Ravimohan S, Tamuhla N, Nfanyana K, Steenhoff AP, Letlhogile R, Frank I, MacGregor RR, Gross R, Weissman D, Bisson GP.
    Clin Infect Dis; 2016 Mar 15; 62(6):795-803. PubMed ID: 26611774
    [Abstract] [Full Text] [Related]

  • 3. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects.
    Toossi Z, Funderburg NT, Sirdeshmuk S, Whalen CC, Nanteza MW, Johnson DF, Mayanja-Kizza H, Hirsch CS.
    J Infect Dis; 2013 Jun 15; 207(12):1841-9. PubMed ID: 23479321
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F.
    Antivir Ther; 2013 Jun 15; 18(4):615-22. PubMed ID: 23423604
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, de Pundert ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL.
    AIDS; 2018 May 15; 32(8):1043-1051. PubMed ID: 29547445
    [Abstract] [Full Text] [Related]

  • 8. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M, Shafer LA, Chan S, Kasper K, Keynan Y.
    J Infect Public Health; 2018 May 15; 11(2):265-269. PubMed ID: 28826735
    [Abstract] [Full Text] [Related]

  • 9. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study.
    Kim KH, Yi J, Lee SH.
    Korean J Intern Med; 2015 Sep 15; 30(5):705-13. PubMed ID: 26354065
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N, Uthman OA, Rutherford GW.
    Cochrane Database Syst Rev; 2010 Mar 17; 2010(3):CD008272. PubMed ID: 20238364
    [Abstract] [Full Text] [Related]

  • 13. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.
    Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, Egger M, Africa FI.
    PLoS One; 2013 Mar 17; 8(6):e64392. PubMed ID: 23755122
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa.
    Fatti G, Grimwood A, Nachega JB, Nelson JA, LaSorda K, van Zyl G, Grobbelaar N, Ayles H, Hayes R, Beyers N, Fidler S, Bock P.
    Clin Infect Dis; 2020 Jan 16; 70(3):395-403. PubMed ID: 30877753
    [Abstract] [Full Text] [Related]

  • 18. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.
    Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M, ART-LINC Collaboration of IeDEA.
    AIDS; 2008 Nov 12; 22(17):2291-302. PubMed ID: 18981768
    [Abstract] [Full Text] [Related]

  • 19. Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia.
    Wolday D, Legesse D, Kebede Y, Siraj DS, McBride JA, Striker R.
    PLoS One; 2020 Nov 12; 15(10):e0240880. PubMed ID: 33091053
    [Abstract] [Full Text] [Related]

  • 20. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.
    JAMA; 2001 Nov 28; 286(20):2568-77. PubMed ID: 11722271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.